Company news
TransCode Therapeutics, Inc. news in 2024
TransCode Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX MC138 Clinical Trial Form 8 K
December 20, 2024
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial
December 17, 2024
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
November 28, 2024
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
November 26, 2024
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
November 24, 2024
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
November 4, 2024
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
October 22, 2024
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
October 9, 2024
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
September 16, 2024
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
September 9, 2024
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
September 4, 2024
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
August 14, 2024
TransCode Therapeutics, Inc. Announces Closing of Public Offering
July 23, 2024
TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
July 21, 2024
TransCode Therapeutics, Inc. Announces Pricing of Public Offering
July 21, 2024
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
May 28, 2024
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
April 14, 2024
TransCode Therapeutics Reports 2023 Results; Provides Business Update
April 2, 2024
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
March 27, 2024
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
February 19, 2024
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
January 21, 2024
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
January 17, 2024
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
January 11, 2024
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
January 10, 2024
Decks in 2024
- Investor Presentation (October 2024)
Investor deck · 19 slides · Oct 28, 2024